Reteplase (Retavase)

Reteplase is a real, FDA-approved genetically re-engineered variant of alteplase, approved in 1996 for the same heart-attack indication with simpler two-bolus dosing — its own approval trial found no survival advantage over alteplase despite the easier dosing, though a large 2024 Chinese trial found it actually outperforms alteplase for a disease it isn't approved to treat in the US: acute ischemic stroke.

A deletion-mutant redesign, built for simpler dosing

Reteplase is a genetically engineered deletion mutant of alteplase itself: three of the five structural domains of native tissue plasminogen activator — the finger, epidermal-growth-factor, and kringle-1 domains — were removed, leaving only the kringle-2 and protease domains that actually break down fibrin. That truncation gives reteplase a longer plasma half-life than alteplase, letting it be given as two fixed 10-unit IV boluses 30 minutes apart rather than a weight-based infusion timed over 60-90 minutes — a genuine practical simplification for time-pressured emergency dosing. It was originally developed by Boehringer Mannheim (later absorbed into Roche) and is marketed in the US today by Chiesi USA as Retavase, with its active ingredient manufactured by Wacker Biotech.

The approval trials: equivalent to streptokinase, not superior to alteplase

FDA approval (30 October 1996) rested on two trials with different comparators and different results. The INJECT trial (International Joint Efficacy Comparison of Thrombolytics, "Randomised, Double-Blind Comparison of Reteplase Double-Bolus Administration with Streptokinase in Acute Myocardial Infarction," Lancet 1995;346(8971):329-336, PMID 7623530) compared reteplase against streptokinase in 6,010 acute-MI patients and found 35-day mortality statistically equivalent (9.02% vs. 9.53%), with reteplase also showing fewer cases of heart failure and cardiogenic shock. The more consequential comparison, against alteplase itself, was less favorable: GUSTO-III (GUSTO III Investigators, "A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction," N Engl J Med 1997;337(16):1118-1123, PMID 9340503), a 15,059-patient trial, found 30-day mortality of 7.47% on reteplase versus 7.24% on alteplase (adjusted p=0.54) — a difference the trial's own prespecified statistical criteria could not call equivalent, let alone superior. Reteplase's real, demonstrated advantage over the drug it was designed to improve on was ease of administration, not outcomes.

A 2024 Chinese trial found it beats alteplase — for a disease it isn't approved to treat

More than a quarter-century later, a large Chinese trial reopened the reteplase-vs-alteplase question for an entirely different disease. The RAISE trial (Li S, Gu HQ, Li H, et al., "Reteplase versus Alteplase for Acute Ischemic Stroke," N Engl J Med 2024;390(24):2264-2273, PMID 38884332), a 1,412-patient, multicenter, randomized, non-inferiority trial run through the Chinese Stroke Association, found reteplase not just non-inferior but statistically superior to alteplase for acute ischemic stroke within 4.5 hours of symptom onset: 79.5% of reteplase patients had an excellent 90-day functional outcome (modified Rankin Scale 0-1) versus 70.4% on alteplase, at the cost of a higher overall intracranial hemorrhage rate (though symptomatic intracranial hemorrhage and death were similar between groups). That is a genuinely notable result — but it used a Chinese-manufactured reteplase product and a different dosing regimen than the US Retavase label, and it has not led to any FDA stroke filing, US confirmatory trial, or label change. In the US, reteplase remains approved for acute myocardial infarction alone.

Current status

Retavase remains FDA-approved and commercially available in the US, but plays a minor role next to alteplase and tenecteplase: primary percutaneous coronary intervention (angioplasty) has become the preferred reperfusion strategy for acute MI at most US hospitals with immediate catheterization-lab access, leaving all three thrombolytics on this site — including reteplase — reserved mainly for patients at facilities without that capability, or requiring transfer. No reteplase biosimilar exists in the US, and unlike tenecteplase, reteplase has not been the subject of any FDA stroke-indication filing as of this review. It carries no wellness, cosmetic, or self-administered use of any kind.